Bausch + Lomb (BLCO) is likely to post a Q4 beat on foreign exchange tailwinds and robust performance of its dry-eye disease portfolio, RBC Capital Markets said in a Tuesday research note.

Ahead of the release of the company's Q4 results on Feb. 18, RBC said it expects Q4 revenue of $1.39 billion, supported by an FX benefit of $28 million and contact lens revenue of $268 million.

For Q4, the brokerage expects Xiidra revenue of $100 million and revenue from Miebo of $94 million.

For full-year 2026, RBC expects revenue of $5.39 billion, including $30 million of FX tailwinds. It also expects Miebo to turn profitable this year, according to the note.

The brokerage reiterated its outperform rating on the stock and raised its price target to $21 from $19.

Price: 17.04, Change: +0.17, Percent Change: +1.01